The Clinical Core is critical to the function of the Indiana Alzheimer Disease Center. Its role is to recruit, clinically characterize and longitudinally follow patients with MCI, AD, non-AD and mixed dementia and healthy controls. A major emphasis is to identify and clinically characterize families with AD and new genetically distinct non-AD dementias with emphasis on identifying patients in the earliest stages of illness. These patients will be further characterized by the Neuropathology Core. In conjunction with the Neuropathology Core, the Clinical Core will obtain and bank biology materials (DNA, plasma and CSF) from participating subjects to support studies pertaining to dementias. Patients from the Clinical Core will be offered as appropriate participation in ADNI, LOAD, investigational drug trials and other local and multicenter research studies. We will continue to support the NCRAD. We will continue our educational efforts in the general elderly as well as African American communities to communicate and facilitate autopsy. After autopsy, clinical-genetic-neuropathological correlation will increase the understanding of AD and non-AD dementias and support further investigations of biochemical abnormalities and/or underlying disease mechanisms.
It is estimated that as many as 5 million Americans have AD. The Indiana Alzheimer Disease Center provides an environment and resources directed towards fostering and coordinating research and educational activities on AD and other dementing illnesses.
|Zhou, Zilu; Wang, Weixin; Wang, Li-San et al. (2018) Integrative DNA copy number detection and genotyping from sequencing and array-based platforms. Bioinformatics 34:2349-2355|
|Ridge, Perry G; Wadsworth, Mark E; Miller, Justin B et al. (2018) Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping. Alzheimers Dement 14:514-519|
|Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25|
|Di Fede, Giuseppe; Catania, Marcella; Maderna, Emanuela et al. (2018) Molecular subtypes of Alzheimer's disease. Sci Rep 8:3269|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Konar, Arpita; Kumar, Ashish; Maloney, Bryan et al. (2018) A serine protease KLK8 emerges as a regulator of regulators in memory: Microtubule protein dependent neuronal morphology and PKA-CREB signaling. Sci Rep 8:9928|
|Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
|Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325|
|Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487|
Showing the most recent 10 out of 604 publications